Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This study will evaluate changes in liver fat content following multiple oral doses of
MK-4074 and Pioglitazone Hydrochloride in adult males and females with fatty liver disease.
The primary hypothesis of the study is that a multiple-dose administration of MK-4074 200 mg
twice daily for 4 weeks results in a decrease in hepatic fat content with respect to placebo
in adult male and female participants with hepatic steatosis (i.e., on order of 50% reduction
in hepatic fat with respect to placebo is expected).